In March, 23andMe said that it was looking to sell “substantially all of its assets” through a court-approved reorganization plan.

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against Billionaire Mario Gabelli’s other large-cap stock picks with huge upside potential.

Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price objective reduced by Truist Financial from $975.00 to $940.00 in a research note released on Wednesday,Benzinga reports.

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. Discussing two decades of Mad Money, Jim Cramer took a moment ...

Regeneron Pharmaceuticals ... This agreement, along with our $3.6 billion expansion of our Tarrytown, New York, R&D and preclinical manufacturing facilities, our fill/finish facility in Rensselaer ...

Regeneron has leveraged its monoclonal antibody research and development platform to become one of the few biotechs to emerge as a profitable commercial operation and establish a narrow moat.

Regeneron’s bispecific antibody linvoseltamab has received conditional approval from the European Commission (EC) for use in relapsed or refractory multiple myeloma. The decision comes just eight ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...

Regeneron shares were down nearly 9% in afternoon trading and have lost more than a fifth of their value so far this year. Tarrytown, N.Y.-based Regeneron also said that its plan to make its ...

Regeneron Pharmaceuticals, Inc. REGN reported first-quarter 2025 adjusted earnings per share (EPS) of $8.22, which missed the Zacks Consensus Estimate of $8.43. The reported figure was down 14% ...